Compounds provided herein are novel substituted pyrazinones, pyridines and
pyrimidines of Formula (I) and (II): ##STR00001## Such compounds are
particularly useful as CRF receptor ligands, and hence, in the treatment
of various neurologically-related disorders such as affective disorder,
anxiety and depression.